FDA Approves Extended-Release Xeljanz for Adults with Ulcerative Colitis

FDA Approves Extended-Release Xeljanz for Adults with Ulcerative Colitis
0
(0)

The U.S. Food and Drug Administration (FDA) has approved Pfizer‘s extended-release tablets of Xeljanz XR (tofacitinib) to treat adults with moderately to severely active ulcerative colitis.

This approval of 11 mg and 22 mg doses offers these patients the option of taking the medication once, rather than twice, per day.

“Ulcerative colitis is a chronic inflammatory disease of the colon that can significantly affect a patient’s quality of life and be emotionally burdensome due to symptoms, flares and complications,” Michael Corbo, PhD, chief development officer of inflammation and immunology at Pfizer Global Product Development, said in a press release.

“We are pleased to now offer patients with moderately to severely active ulcerative colitis and their healthcare providers a convenient once-daily dosing option with XELJANZ,” Corbo added.

Xeljanz was first approved by the FDA for the same indication in 2018 as a 10 mg, twice-daily oral therapy taken for at least eight weeks, after which patients could continue on either 5 mg or 10 mg twice a day.

With the newly approved extended-release version, patients can take 22 mg of Xeljanz XR once a day for eight weeks or up to a maximum of 16 weeks as induction therapy.

After the induction period, patients may take 11 mg of Xeljanz XR once a day as maintenance treatment.

For patients who have an inadequate response during the maintenance treatment period, physicians can prescribe either 10 mg Xeljanz twice a day or 22 mg Xeljanz XR once a day.

However, this higher dose in the maintenance period should be taken for the shortest time possible and only after carefully considering the risk and benefit to individual patients. Physicians should also use the lowest dose that can still effectively maintain a response.

Dose adjustments may be needed for patients who have moderate and severe kidney impairment or moderate liver impairment.

Xeljanz is an inhibitor of Janus kinases (JAK), which are enzymes that promote pro-inflammatory proteins involved in the development of autoimmune diseases such as ulcerative colitis. The therapy is indicated for patients who have had an inadequate response or are intolerant to TNF blockers, such as Humira (adalimumab).

It is not recommended that either Xeljanz or Xeljanz XR be used in combination with biological therapies for ulcerative colitis or with immunosuppressant medications, such as azathioprine and cyclosporine.

Iqra holds a MSc in Cellular and Molecular Medicine from the University of Ottawa in Ottawa, Canada. She also holds a BSc in Life Sciences from Queen’s University in Kingston, Canada. Currently, she is completing a PhD in Laboratory Medicine and Pathobiology from the University of Toronto in Toronto, Canada. Her research has ranged from across various disease areas including Alzheimer’s disease, myelodysplastic syndrome, bleeding disorders and rare pediatric brain tumors.
Total Posts: 455
Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.
×
Iqra holds a MSc in Cellular and Molecular Medicine from the University of Ottawa in Ottawa, Canada. She also holds a BSc in Life Sciences from Queen’s University in Kingston, Canada. Currently, she is completing a PhD in Laboratory Medicine and Pathobiology from the University of Toronto in Toronto, Canada. Her research has ranged from across various disease areas including Alzheimer’s disease, myelodysplastic syndrome, bleeding disorders and rare pediatric brain tumors.
Latest Posts
  • Stelara
  • Substance Use Disorder (SUD)
  • Anti-Interleukin-1α Antibody
  • Xeljanz XR approval

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?